CGONCG Oncology, Inc.
$63.86+73% 1Y
$63.86
$36.4852 weeks$80.66
The financials
CG Oncology, Inc. by the numbers
CG Oncology, Inc. (CGON) reported revenue of $1.2M in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $79M. For the full year FY2025, revenue was $4.0M (+255% year on year) and net income −$161M. Its largest product in Q2 2026 was Commercial And Development at $1.1M, 99% of the disclosed total, well ahead of License And Collaboration at 0.9%. The next results filing is expected around Nov 13, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.2M | $0 | n/a |
| Operating income | −$86M | −$49M | n/a |
| Net income | −$79M | −$41M | n/a |
| Diluted EPS | −$0.90 | −$0.54 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Commercial And Development | $1.1M | 99% |
| License And Collaboration | $10K | 0.9% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $1.2M (+6.8%)
Segment Latestquarter on quarteryear on year
- Commercial And Development$1.1M$1.1Mquarter on quarter +7.3%year on year n/a+7.3%n/a
- License And Collaboration$10.0K$10.0Kquarter on quarter -29%year on year n/a-29%n/a
On our screens:Most shorted stocks
Biotechnology
The closest names by size in the same industry